Economic Costs Analysis of the Avoidable Mortality in Colombia 1998–2011 Diana Díaz-Jiménez, Esp, Carlos Castañeda-Orjuela, MD, MSc, Liliana Castillo-Rodríguez,

Slides:

Advertisements

Similar presentations

Harvard University Initiative for Global Health Global Health Challenges Social Analysis 76: Lecture 4.

Advertisements

Joseph Perriëns MD, PhD Dept of HIV/AIDS World Health Organization

Cost-Effectiveness of Sensor-Augmented Pump Therapy in Adults with Type 1 Diabetes in the United States Shital Kamble, PhD, Kevin A. Schulman, MD, Shelby.

Value in Health Regional Issues

Global deaths by cause, CMNN, communicable, maternal, neonatal, and nutritional disorders; CVD, cardiovascular diseases; INJ, injuries; ONC, other.

Cost-effectiveness Analysis of Viscosupplementation versus Conventional Supportive Therapy for Knee Osteoarthritis in Colombia Juan-Carlos Castro, MD,

Work Productivity and Costs Related to Patients with Ankylosing Spondylitis, Rheumatoid Arthritis, and Psoriasis Klára Kruntorádová, MSc, Jiří Klimeš,

The Health Economic Impact of Universal Infant Vaccination with the 10-Valent Pneumococcal Nontypeable Haemophilus influenzae Protein D Conjugate Vaccine.

Value in Health Regional Issues

An Audit of Diabetes-Dependent Quality of Life (ADDQOL) in Older Patients with Diabetes Mellitus Type 2 in Slovenia Eva Turk, MA, MBA, Valentina Prevolnik.

Dengue Epidemiology and Burden of Disease in Latin America and the Caribbean: A Systematic Review of the Literature and Meta-Analysis María Luisa Cafferata,

The Development of the Romanian Scorecard HTA System

Using Dynamic Transmission Modeling to Determine Vaccination Coverage Rate Based on 5-Year Economic Burden of Infectious Disease: An Example of Pneumococcal.

Prognosis, Cost, and Occurrence of Colorectal, Lung, Breast, and Prostate Cancer in Hungary András Inotai, PharmD, PhD, Zsolt Abonyi-Tóth, MSc, György.

Value in Health Regional Issues

Systematic Review of Economic Evaluation Literature in Ghana: Is Health Technology Assessment the Future? Emmanuel Ankrah Odame, MBCHB, MPH Value in.

The Cost-Effectiveness Analysis of a Quadrivalent Human Papillomavirus Vaccine (6/11/16/18) for Females in Japan Kaoru Yamabe, MSc, Puneet K. Singhal,

Prevalence, Awareness, Treatment, and Burden of Major Depressive Disorder: Estimates from the National Health and Wellness Survey in Brazil Ronaldo K.

Value in Health Regional Issues

Dengue Epidemiology and Burden of Disease in Latin America and the Caribbean: A Systematic Review of the Literature and Meta-Analysis María Luisa Cafferata,

The Process of Privatization of Health Care Provision in Poland

Boxiong Tang, MD, PhD, Eran Harary, MD, Ricky Kurzman, MSc, Joaquín F

Ernest Attuquaye Quaye, BPharm, MPH, Edward O

Work Productivity and Costs Related to Patients with Ankylosing Spondylitis, Rheumatoid Arthritis, and Psoriasis Klára Kruntorádová, MSc, Jiří Klimeš,

Value in Health Regional Issues

WHO Statistics, 2000 Dr. Rüdiger Krech

Cost-Benefit Analysis and Assessment of Quality of Care in patients with Hemophilia undergoing treatment at National Rural Health Mission in Maharashtra,

Economic Evaluation of Bariatric Surgery in Mexico Using Discrete Event Simulation Olivo Omar Zanela, MSc, Hermilo Arturo Cabra, MSc, Guillermo Meléndez,

Value in Health Regional Issues

What Is Important During the Selection of Traditional Chinese Medicine (TCM) in a Health Care Reimbursement or Insurance System?” Critical Issues of Assessment.

Assessment of Effect of Diabetes on Health-Related Quality of Life in Patients with Coronary Artery Disease Using the EQ-5D Questionnaire Bhavik Shah,

Jinhyun Kim, PhD, Eunhee Lee, PhD, Sungjae Kim, PhD, Tae Jin Lee, PhD

Burden of Disease and Economic Impact of Dengue and Severe Dengue in Colombia, 2011 Carlos Castañeda-Orjuela, MD, MSc, Hernando Díaz, PhD, Nelson Alvis-Guzman,

The Potential Effects of Implementing the 2013 ACC/AHA Cholesterol Guidelines on the Use of Statins in a Large Health Maintenance Organization in Israel

Cost-Effectiveness Analysis of Atorvastatin versus Rosuvastatin in Primary and Secondary Cardiovascular Prevention Populations in Brazil and Columbia

Bernadette A. Tumanan-Mendoza, MD, MScE, MHE, Victor L. Mendoza, MD

Patient-Reported Outcomes in Latin America: Implementation in Research and Role in Emerging HTA Systems Randall Winnette, MSc, Victor Zárate, MD, MSc,

Omneya Mohamed, PhD, David H. Kreling, PhD

Onur Baser, MS, PhD, Akif Altinbas, MD, Erdem Baser, MS, M

The relationships between democratic experience, adult health, and cause-specific mortality in 170 countries between 1980 and 2016: an observational analysis

Burden of Disease Studies in the Asia-Pacific Region: Are There Enough being Performed to Provide Information for Evidence-Based Health Policy? Fei-Li.

Prognosis, Cost, and Occurrence of Colorectal, Lung, Breast, and Prostate Cancer in Hungary András Inotai, PharmD, PhD, Zsolt Abonyi-Tóth, MSc, György.

Children Hospitalized for Varicella: Complications and Cost Burden

Transforming Public Servants’ Health Care Organization in Greece through the Implementation of an Electronic Referral Project Kyriakos Souliotis, PhD,

Impact of carbapenem resistance on clinical and economic outcomes among patients with Acinetobacter baumannii infection in Colombia E.V. Lemos, F.P.

Economic Burden of Individual Suffering from Atrial Fibrillation–Related Stroke in China Shanlian Hu, MSc, Lin Zhan, MSc, Bao Liu, MD, PhD, Yue Gao, MD,

Generalized Cost-Effectiveness Analysis of Pharmaceutical Interventions for Primary Prevention of Cardiovascular Disease in Thailand Panrasri Khonputsa,

The Methodological Challenges for the Estimation of Quality of Life in Children for Use in Economic Evaluation in Low-Income Countries Travor Mabugu,

Volume 374, Issue 9693, Pages (September 2009)

Reconciling Cancer Care Costs Reported by Different Government Agencies in Taiwan: Why Costing Approach Matters? Chun-Ru Chien, MD, PhD, Ya-Chen Tina.

Cost-effectiveness Analysis of Viscosupplementation versus Conventional Supportive Therapy for Knee Osteoarthritis in Colombia Juan-Carlos Castro, MD,

Incidence of Intravenous Medication Errors in a Chinese Hospital

Economic Evaluation of Pravastatin for Primary Prevention of Coronary Artery Disease Based on Risk Prediction from JALS-ECC in Japan Yoshie Onishi, MS,

The Cost-Effectiveness and Budget Impact of Introducing Indacaterol into the Colombian Health System Juan Guillermo Ariza, MD, MSc, Per-Olof Thuresson,

Pei Wang, PhD, Nan Luo, PhD, E.S. Tai, PhD, Julian Thumboo, PhD

Guidance Document: Global Pharmacoeconomic Model Adaption Strategies

Value in Health Regional Issues

Prediction of Change in Prescription Ingredient Costs and Co-payment Rates under a Reference Pricing System in South Korea Ji Haeng Heo, MS, Karen L.

Dossier System as a Practical Tool for Compiling Reimbursement Lists

Colombian Health System on its Way to Improve Allocation Efficiency—Transition from a Health Sector Reform to the Settlement of an HTA Agency Nicolás.

Cost-Minimization Analysis of Direct Cost of Sevelamer Carbonate and Lanthanum Carbonate in the Treatment of Patients with Chronic Kidney Disease Not.

Value in Health Regional Issues

Evaluating the Long-Term Health Economic Implications of Improving the Proportion of Patients with Type 2 Diabetes Meeting Treatment Targets in Mexico

Social Cost of Substance Abuse in Russia

Economic Evaluation of Four Drug Administration Systems in Intensive Care Units in Colombia Diego Rosselli, MD, MSc, Juan David Rueda, MD, María Daniela.

Clinical Burden of Invasive Pneumococcal Disease in Selected Developing Countries Namaitijiang Maimaiti, PhD, Zafar Ahmed, PhD, Zaleha Md Isa, PhD, Hasanain.

Victoria I. Ignatyeva, MPH, Johan L

A Comparison of 1-Year Treatment Costs in Patients with Type 2 Diabetes Following Initiation of Insulin Glargine or Insulin Detemir in Argentina Joaquín.

Economic Burden of Incident Unplanned Starts on Peritoneal Dialysis in a High Specialty Health Care Facility in Mexico City Sergio O. Hdez Ordonez, MD,

Abdol Majid Cheraghali, PhD, Peyman Eshghi, MD

Presentation transcript:

Economic Costs Analysis of the Avoidable Mortality in Colombia 1998–2011 Diana Díaz-Jiménez, Esp, Carlos Castañeda-Orjuela, MD, MSc, Liliana Castillo-Rodríguez, MSc, Fernando De la Hoz-Restrepo, MD, PhD Value in Health Regional Issues Volume 8, Pages 129-135 (December 2015) DOI: 10.1016/j.vhri.2015.08.007 Copyright © 2015 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

Fig. 1 Low and upper limits for annual salaries according to the year of loss in 2012 US dollars. AMW, annual minimum wage; pcGDP, per capita gross domestic product. Value in Health Regional Issues 2015 8, 129-135DOI: (10.1016/j.vhri.2015.08.007) Copyright © 2015 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

Fig. 2 Avoidable mortality costs in working age by year and sex: Colombia (1998–2011) (in thousands of 2012 USD). Value in Health Regional Issues 2015 8, 129-135DOI: (10.1016/j.vhri.2015.08.007) Copyright © 2015 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

Fig. 3 Avoidable mortality costs in the best-case scenario per 22 GBD group causes: Colombia (1998–2011). HIV, HIV/AIDS; TB, Tuberculosis; Dia, Diarrhea; LRI, Lower respiratory infections; Oth, other common infectious diseases; NTD, Neglected tropical diseases; Maternal, Maternal disorders; Neonatal, Neonatal disorders; Ntr Def, Nutritional deficiencies; CVD, Cardiovascular and circulatory diseases; Chr Resp, Chronic respiratory diseases; Neuro, Neurological disorders; Mental, Mental and behavioral disorders; Diab, Diabetes; Urog, urogenital; Hem, blood; MSK, Musculosketeal disorders; NCD, Other non-communicable diseases; Tran Inj, Transport injuries; Unint Inj, Unintentional injuries other than transport injuries; Intent Inj, Self-harm and interpersonal violence; disaster, forces of nature; Undet int Inj, Injuries with undetermined intent; GBD, global burden disease. Value in Health Regional Issues 2015 8, 129-135DOI: (10.1016/j.vhri.2015.08.007) Copyright © 2015 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

Fig. 4 Avoidable mortality costs in the worst-case scenario per 22 GBD group causes: Colombia (1998–2011). HIV, HIV/AIDS; TB, Tuberculosis; Dia, Diarrhea; LRI, Lower respiratory infections; Oth, other common infectious diseases; NTD, Neglected tropical diseases; Maternal, Maternal disorders; Neonatal, Neonatal disorders; Ntr Def, Nutritional deficiencies; CVD, Cardiovascular and circulatory diseases; Chr Resp, Chronic respiratory diseases; Neuro, Neurological disorders; Mental, Mental and behavioral disorders; Diab, Diabetes; Urog, urogenital; Hem, blood; MSK, Musculosketeal disorders; NCD, Other non-communicable diseases; Tran Inj, Transport injuries; Unint Inj, Unintentional injuries other than transport injuries; Intent Inj, Self-harm and interpersonal violence; disaster, forces of nature; Undet int Inj, Injuries with undetermined intent; GBD, global burden disease. Value in Health Regional Issues 2015 8, 129-135DOI: (10.1016/j.vhri.2015.08.007) Copyright © 2015 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions